Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
09 2월 2024 - 6:00AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
products for serious rare and ultrarare genetic diseases, today
announced that it will host a conference call at 5:00 p.m. ET on
Thursday, February 15, 2024, to discuss its financial results and
corporate update for the fourth quarter and the year ending
December 31, 2023.
The live and replayed webcast of the call will be
available through the company’s website at
https://ir.ultragenyx.com/events-presentations. To participate in
the live call, please register by clicking on the following link
(registration link) and you will be provided with dial-in details.
The replay of the call will be available for 3 months.
About Ultragenyx Pharmaceutical
Inc.Ultragenyx is a biopharmaceutical company committed to
bringing novel products to patients for the treatment of serious
rare and ultrarare genetic diseases. The company has built a
diverse portfolio of approved therapies and product candidates
aimed at addressing diseases with high unmet medical need and clear
biology for treatment, for which there are typically no approved
therapies treating the underlying disease.
The company is led by a management team experienced
in the development and commercialization of rare disease
therapeutics. Ultragenyx’s strategy is predicated upon time- and
cost-efficient drug development, with the goal of delivering safe
and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit
the company's website at: www.ultragenyx.com.
Contact Ultragenyx
InvestorsJoshua Higa(415) 475-6370
MediaCarolyn Wang(415) 225-5050
Ultragenyx Pharmaceutical (NASDAQ:RARE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024